1. Introduction {#sec1}
===============

Late transient neonatal hypocalcemia with hyperphosphatemia is a potentially life-threatening condition first reported in the 1930s. The condition presents between days of life 3--14, typically with tetanic seizures in a previously healthy term neonate \[[@B1]\]. This condition is rarely seen in breast-fed infants and is believed to be associated with a high phosphate load in the formula \[[@B2], [@B3]\]. Introduction of formulas with lower phosphate loads has not eliminated the occurrence of transient neonatal hypocalcemia \[[@B1], [@B4]--[@B8]\]. This condition continues to be seen with a frequency of 30/10,000 among formula-fed neonates \[[@B2], [@B8]\]. The standard treatment of symptomatic neonatal hypocalcemia is intravenous calcium infusion \[[@B8], [@B9]\].Extravasation of intravenous calcium can result in severe tissue necrosis \[[@B3]\]. IV infiltration rates among neonates vary from 57% to 70% and extravasation occurs in 11% to 23% of reported cases \[[@B10]--[@B12]\]. The most common cause of IV infiltration is total parenteral nutrition (76%) and calcium (72%) \[[@B11], [@B12]\]. In addition, intravenous calcium has also been associated with cardiac arrhythmias, notably bradycardia. The use of 1,25-Dihydroxyvitamin D \[1,25(OH)~2~Vitamin D\] in the management of transient hypocalcemia is less clear \[[@B3], [@B9]\]. 1,25(OH)~2~ Vitamin D might reduce the time of correction of hypocalcemia and the duration of intravenous calcium administration by stimulating calcium mobilization from the bones, reducing renal proximal tubular excretion of calcium, and promoting absorption of calcium from the duodenum during hypocalcemia \[[@B9], [@B13], [@B14]\].

To our knowledge there are no controlled studies that have evaluated the effect of adding 1,25(OH)~2~ Vitamin D to intravenous continuous calcium infusion for late transient neonatal hypocalcemia. We hypothesized that the addition of 1,25(OH)~2~ Vitamin D to standard intravenous continuous calcium infusion would achieve more rapid resolution of hypocalcemia and shorten the duration of intravenous continuous calcium infusion when compared with intravenous continuous calcium infusion alone.

2. Study Design {#sec2}
===============

Following approval by the Baylor College of Medicine\'s Institutional Review Board, subjects were prospectively enrolled in this double-blind, randomized clinical study. Patients were randomized by pharmacy staff and they were the only ones aware of what therapy infants were receiving. Term infants 3--14 days old weighing ≥2000 grams were eligible for the study if they presented with hypocalcemia (ionized calcium ≤1.0 mmol/L or total calcium ≤8.0 mg/dL), hyperphosphatemia (phosphorus ≥ 6.0 mg/dL), and seizures. All infants had to demonstrate a normal cardiothymic silhouette on chest radiograph and have no known congenital anomalies. Recruitment occurred at Texas Children\'s Hospital between February 2004 through April 2005. Patients were excluded if there was any history of anticonvulsant use, subsequent diagnosis of DiGeorge Syndrome by FISH, or confirmed sepsis. Infants were also excluded if the mother had diabetes mellitus or a known disorder of calcium metabolism.

Intravenous calcium levels and other baseline laboratory studies were collected once hypocalcemia was suspected. Informed consent was obtained within 6 hours of admission. Infants were randomized to receive 0.25 micrograms of 1,25(OH)~2~ Vitamin D or placebo (saline) daily after intravenous continuous calcium infusion was initiated. Time of correction of hypocalcemia was defined as the time from initiation of intravenous continuous calcium infusion to the first measured ionized calcium level of ≥1.1 mmol/L. Duration of intravenous continuous calcium infusion was defined as the time from initiation of intravenous continuous calcium infusion to the time when intravenous continuous calcium infusion was discontinued.

The evaluation, titration, and dosing of intravenous continuous calcium infusion were based on the clinical protocol described below. The following baseline diagnostic studies were collected to evaluate the etiology of hypocalcemia: total calcium, ionized calcium, serum phosphorus, serum magnesium, intact parathyroid hormone, 25(OH) Vitamin D, 1,25(OH)~2~Vitamin D, FISH for DiGeorge Syndrome and AP chest radiograph. Maternal etiologies of hypocalcemia included diabetes, vitamin D deficiency, and hyperparathyroidism. These were evaluated by measuring maternal HbA1C, 25(OH) Vitamin D, 1,25(OH)~2~ Vitamin D, intact parathyroid hormone, serum ionized calcium, phosphorus and magnesium levels. After all diagnostic studies were collected, a bolus of 10 mg of elemental calcium/kg was administered intravenously over 30 minutes. Infants were then started on an intravenous continuous calcium infusion of 100 mg elemental calcium/kg/day. Ionized serum calcium and phosphorus levels were obtained every 4--6 hours. The intravenous continuous calcium infusion was titrated to maintain ionized serum calcium levels between 1.1-1.2 mmol/L. Hypomagnesemia was corrected if serum magnesium was ≤1.5 mg/dL. If serum ionized calcium levels were ≥1.2 mmol/L, the intravenous continuous calcium infusion was reduced using the same algorithm in both groups. Infants were started on Similac PM 60/40 (a low phosphate load formula) or breast milk when ionized calcium was ≥1.1 mmol/L and there was no seizure activity within the past 2 hours. Oral calcium was started once infants tolerated their first feeding. Initial dose of oral calcium was 25 mg elemental calcium/kg/day given in 4 daily doses (every 6 hours). Two hours after the first oral calcium dose was administered, the intravenous continuous calcium infusion was reduced by an amount corresponding to the oral calcium dose. If the ionized calcium level was ≥1.1 mmol/L on two separate measurements assuring that calcium level had consistently remained stable and the infant tolerated feeds, infants were switched from intravenous to oral calcium dosing. Intravenous continuous calcium infusion was discontinued 2 hours after the switch to full oral dosing. Serum ionized calcium, phosphorus, and total calcium were checked three hours after the intravenous continuous calcium infusion was discontinued. Once intravenous continuous calcium infusion was stopped, serum calcium and phosphorus levels were obtained every 12 hours and 1,25(OH)~2~ Vitamin D or placebo daily was changed from intravenous to oral delivery.

3. Statistical Analysis {#sec3}
=======================

All data in the results section are expressed as mean ± standard error. Analysis of covariance (ANCOVA) was used to analyze time of correction of hypocalcemia and time to discontinue intravenous continuous calcium infusion. Initial ionized calcium was covariate in the analysis. Students *t*-test was used to analyze the difference in weight, age at seizures, baseline laboratories and maternal laboratories.

4. Results {#sec4}
==========

Fourteen formula-fed neonates were studied \[7 receiving placebo, 7 receiving 1,25(OH)~2~ Vitamin D\]. Four infants received less than 4 oz (120cc) a day of expressed breast milk. The formulas used included Enfamil LIPIL with Iron (9 infants), Similac Advance (3 infants), Enfamil LactoFree LIPIL (1 infant), and Similac Isomil Advance (1 infant). Ten infants were Hispanic (8 male/2 female) and 4 Caucasian (all males). All results are expressed as mean ± SEM. Baseline data and laboratory tests are summarized in [Table 1](#tab1){ref-type="table"}.

There was no statistical difference between the placebo and 1,25(OH)~2~ Vitamin D group with regard to age at first seizure, age of admission, weight, and all baseline tests except phosphorus ([Table 1](#tab1){ref-type="table"}). The placebo group had a higher initial serum phosphorus level \[*P* = .03; unpaired *t*-test when compared to 1,25(OH)~2~ Vitamin D group\]. All maternal diagnostic tests were normal, except 25(OH) Vitamin D which was low ([Table 1](#tab1){ref-type="table"}). 1,25(OH)~2~ Vitamin D was initiated 4.8 ± 0.5 hours after starting intravenous continuous calcium infusion due to processing of the study and preparing medication in pharmacy. The time of correction of hypocalcemia for 1,25(OH)~2~ Vitamin D group versus placebo was 7.2 ± 1.9 versus 11.5 ± 3.4 hours, respectively, (*P* = .26). Duration of intravenous continuous calcium infusion was 15.0 ± 1.5 versus 24.8 ± 4.4 hours, respectively (*P* = .012) ([Figure 1](#fig1){ref-type="fig"}). Intravenous continuous calcium infusion was not restarted in any of the neonates once it was discontinued. No tissue necrosis or other complications occurred in any of the neonates during the study.

5. Discussion {#sec5}
=============

Neonatal hypocalcemia is clinically divided into early and late presentation. Early neonatal hypocalcemia is defined as occurring in the first 48 hours of life. The differential diagnosis includes prematurity, intrauterine growth retardation, and birth asphyxia \[[@B3], [@B9]\]. Maternal factors including gestational diabetes, vitamin D deficiency, and hyperparathyroidism can also cause early neonatal hypocalcemia \[[@B3], [@B9], [@B15]--[@B17]\]. Late neonatal hypocalcemia is generally defined as hypocalcemia presenting with seizures after the 3rd day of life \[[@B18]--[@B22]\]. The differential diagnosis for late neonatal hypocalcemia includes high phosphate load formulas, hypomagnesemia, hypoparathyroidism (including DiGeorge Syndrome), disorders of vitamin D metabolism, bicarbonate infusion, citrate load in transfused blood, lipid infusions, maternal hyperparathyroidism, or any combination of the above \[[@B1]--[@B3], [@B9], [@B20]--[@B22]\]. Our infants were all healthy term infants fed high phosphate formula presenting at the end of the first week of life with hypocalcemia, hyperphosphatemia, hypomagnesemia, and seizures. Almost all reported cases of late transient neonatal hypocalcemia are seen in formula-fed infants (30/10000 compared to 1/10000 in breast-fed infants) \[[@B8]\]. Some authors speculate that the high phosphate load in commercially available formulas combined with immature renal phosphorus excretion and immaturity of the parathyroid hormone response results in a "relative hypoparathyroidism" which is most likely to occur in the first 3 weeks of life resulting in neonatal hypocalcemia \[[@B1], [@B2], [@B4]--[@B8], [@B23], [@B24]\].

Late transient neonatal hypocalcemia continues to be reported despite recent reduction in phosphate load in the commercially available formulas \[[@B1], [@B2], [@B4], [@B5], [@B7], [@B8], [@B23]\]. Infants presenting with hypocalcemic seizures require intravenous calcium to rapidly correct hypocalcemia \[[@B3], [@B9]\]. Extravasation of intravenous calcium can result in severe tissue necrosis \[[@B3]\]. IV infiltration rates among neonates vary from 57% to 70% and extravasation occurs in 11% to 23% of reported cases \[[@B10]--[@B12]\]. The most common cause of IV infiltration is total parenteral nutrition (76%) and calcium (72%) \[[@B11], [@B12]\].

We postulated that the use of 1,25(OH)~2~ Vitamin D in our study population would reduce the time of correction of hypocalcemia. We found that the time to correct hypocalcemia was not statistically different between the placebo and 1,25(OH)~2~ Vitamin D treated groups. Due to the delay processing the study and preparing medication in pharmacy, 1,25(OH)~2~ Vitamin D was initiated 4.8 ± 0.5 hours after starting intravenous continuous calcium infusion. Earlier administration of 1,25(OH)~2~ Vitamin D might have further reduced the time of resolution of hypocalcemia. The onset of action of 1,25(OH)~2~ Vitamin D is approximately 4--6 hours. On average, hypocalcemia was corrected 7.2 ± 1.9 hours after intravenous continuous calcium infusion was started and 4.5 hours after 1,25(OH)~2~ Vitamin D was given. There was probably not enough time for the 1,25(OH)~2~ Vitamin D to mobilize calcium from the bone. The high dose of intravenous continuous calcium used may also have obscured the effect of 1,25(OH)~2~ Vitamin D. The study might have also been underpowered (83%) due to small sample size.

Once calcium was corrected, 1,25(OH)~2~ Vitamin D helped maintaining the ionized calcium concentration above 1.1 mmol/L. This allowed the intravenous continuous calcium infusion to be discontinued 10 hours sooner than in the control group. This 10-hour time difference may reflect the time it takes for 1,25(OH)~2~ Vitamin D to exert its full effect on calcium metabolism. This effect is mediated by 1,25(OH)~2~ Vitamin D stimulating calcium mobilization from the bones since promoting calcium absorption from the duodenum and proximal small intestine is mostly vitamin D independent in neonates \[[@B9], [@B14]\]. Reduction of renal proximal tubular excretion of calcium would also be an expected mechanism of action by 1,25(OH)~2~ Vitamin D during hypocalcemia along with stimulation of non-genomic pathways involving paracellular calcium absorption due to upregulation of Vitamin D receptor and calcium-sensing receptor \[[@B10], [@B13], [@B26]\].

In conclusion, the addition of 1,25(OH)~2~Vitamin D to standard intravenous continuous calcium infusion reduced the infusion duration needed to effectively treat late transient neonatal hypocalcemia. A shorter duration of intravenous continuous calcium infusion may reduce the risk of complications associated with intravenous calcium infusion, such as tissue necrosis due to extravasations and could translate to reduced medical cost.
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![Time to correct hypocalcemia and duration of intravenous calcium infusion by treatment group. (1) Criteria for correction of hypocalcemia: (i) ionized Ca ≥ 1.1 mmol/L, (ii) seizure free for 2 hours. (2) Criteria for discontinuation of IV calcium: (i) ionized Ca ≥ 1.1 mmol/L × 2, (ii) tolerating feeds.](IJPE2010-409670.001){#fig1}

###### 

Demographics and baseline laboratory tests by treatment group.

  (Units)                BirthWeight(kg)   Age (days)   Gender (M/F)   Ethnicity(Hispanic/Caucasian)   Ionized Calcium (mmol/L)           Phosphorus (mg/dL)   Mg (mg/dl)   Intact PTH (pg/mL)   25(OH) Vitamin D (ng/mL)   1,25(OH)~2~Vitamin D (pg/mL)
  ---------------------- ----------------- ------------ -------------- ------------------------------- ---------------------------------- -------------------- ------------ -------------------- -------------------------- ------------------------------
  Placebo                4.06 ± 0.30       5.4 ± 0.5    6/1            6/1                             0.86 ± 0.04                        10.5 ± 0.3\*         1.3 ± 0.1    26.0 ± 4.0           14.2 ± 2.8                 159.4 ± 31.1
                                                                                                                                                                                                                            
  1,25(OH~2~)Vitamin D   3.73 ± 0.21       6.3 ± 0.4    6/1            4/3                             0.88 ± 0.02                        9.4 ± 0.2            1.2 ± 0.1    31.6 ± 4.7           15.1 ± 2.8                 140.3 ± 10.7
                                                                                                                                                                                                                            
  Mean                   3.91 ± 0.16       5.9 ± 0.3                                                   0.87 ± 0.02                        10.0 ± 0.2           1.2 ± 0.1    30.0 ± 3.0           15.0 ± 2.0                 148.0 ± 14.0
                                                                                                                                                                                                                            
  Mother                                                               HgA1C (%) 5.2 ± 0.4             Total Calcium(mg/dl) 9.35 ± 0.35   3.6 ± 0.2            3.0 ± 0.8    65.2 ± 16.3          15.3 ± 4.0                 36.8 ± 5.0

\**P* = .03; *t*-test when compared to 1,25(OH)~2~ Vitamin D group Conversion factors:

Phosphorus mmol/L = mg/dL × 0.32.

Magnesium mmol/L = mg/dL × 0.5.
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